A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome
Phase of Trial: Phase III
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Amifampridine (Primary)
- Indications Lambert-Eaton myasthenic syndrome
- Focus Therapeutic Use
- Sponsors Catalyst Pharmaceutical Partners
- 14 Mar 2017 According to a Biocept Inc. media release, Biocept and Catalyst Pharmaceuticals announce collaboration for the provision of liquid biopsy testing for small cell lung cancer to patients in this trial.
- 15 Dec 2016 Results from this trial and an NDA re-submission are expected in the second half of 2017, according to a Catalyst Pharmaceuticals Inc. media release.
- 15 Dec 2016 According to a Catalyst Pharmaceuticals Inc. media release, the first patient has been enrolled into this trial.